Meta has been on an AI spending spree. Earnings show it's paying off
Meta on Wednesday posted earnings of $7.14 per share on $47.5 billion in revenue from the quarter ended June 30. Earnings per share were up 38% from the year-ago period and well above the $5.88 that Wall Street analysts had expected.
It also projected revenue from the current quarter will be between $47.5 billion and $50.5 billion, also ahead of analysts' expectations.
The strong results sent Meta shares up more than 9% in after-hours trading. The company's stock has risen 16% since the start of this year.
'Meta's blowout earnings and raised guidance highlight how AI is becoming a real revenue driver, not just hype,' Investing.com Senior Analyst Jesse Cohen said in a statement. 'The company's continued heavy investment in AI infrastructure signals it's playing the long game.'
The report came after Meta CEO Mark Zuckerberg laid out his approach to AI 'superintelligence' in a video and blog post on Wednesday morning. He wants everyone to have access to their own personal AI superintelligence, he said in the blog post, making people more productive so they can spend 'more time creating and connecting.'
'Our business continues to perform very well, which enables us to invest heavily in our AI efforts,' Meta said in a call with analysts Wednesday evening, adding that the company's performance in the quarter could be attributed to AI improving its core ad business.
Meta has been shelling out big bucks to recruit top AI talent away from rivals such as OpenAI, Google and Apple for its new Meta Superintelligence Labs team. The company is also spending hundreds of billions of dollars to build massive AI data centers.
On Friday, Zuckerberg announced that Shengjia Zhao, one of the co-creators of ChatGPT who Meta hired away from OpenAI several weeks ago, will be the team's chief scientist.
Meta is in league with tech giants such as OpenAI, Google and Anthropic that are all racing toward superintelligence, the theoretical point at which AI becomes smarter than all humans at all knowledge work. It's believed that if that milestone is reached, it could dramatically reshape the economy and the way people work, potentially creating significant new business opportunities for the companies that can provide the technology.
And the stakes may be especially high for Zuckerberg, who wants Meta to be more than just a social media company and has refocused it on AI after an unsuccessful pivot to the metaverse. The company is under pressure to deliver on the billions it's invested in data centers and chips, and it also has a growing smart glasses business that depends on the success of its AI efforts. And the company is coming from somewhat behind competitors, after reported delays in releasing the largest version of its new Llama 4 AI model.
Zuckerberg said Wednesday morning that he believes smart glasses will be the 'main computing device' for the AI era.
Despite its aggressive spending, Meta on Wednesday said its capital expenditures during the third quarter were $17 billion, nearly in line with Wall Street's estimate of $16.48 billion. And it narrowed — but did not raise — its full-year capital expenditure guidance, giving investors a more precise view of its spending plan.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Factbox-Healthcare firms see growing activist investor involvement in the past year
(Reuters) -Activist investors have targeted major healthcare companies over the past year to push them to improve their performance, with some campaigns only coming to light after announcements of board changes. Below are some notable healthcare companies that came under activist pressure in the last 12 months. MEDTRONIC In August 2025, the medical device maker appointed two new independent directors to its board and created independent committees focused on improving its performance, after Elliott Investment Management took a large stake, making it one of the company's biggest shareholders. AVANTOR Engine Capital targeted the life sciences firm in August 2025, urging it to bring in new board directors, cut costs and even consider a sale. CHARLES RIVER LABORATORIES The contract research firm settled with Elliott Investment Management in May 2025 by agreeing to add four new board directors and launch a strategic review of the business. NOVO NORDISK Activist hedge fund Parvus Asset Management is building a stake in the company, as investors have grown concerned that the Danish drugmaker has lost its first-mover advantage in the lucrative weight-loss drug market, the Financial Times reported in June 2025. Reuters has not independently verified the report. GERRESHEIMER London-based investment fund Asset Value Investors in June 2025 pressed the German medical packaging maker to find ways to restore its market value. AVI, with a 3.5% stake in Gerresheimer, said the company needs a new financial leadership to regain its credibility. ILLUMINA In March 2025, the gene-sequencing maker said activist investor Keith Meister would join its board. HENRY SCHEIN In January, private equity firm KKR built a large stake in the medical and dental supplies distributor and reached a deal to add members to the company's board. Henry Schein was also under pressure from other investors, including Ananym Capital Management. PFIZER Activist hedge fund Starboard Value in October 2024 called for management accountability for the company's underperformance. This month, Starboard increased its holding in the drugmaker to 8.5 million shares, which represented about 0.15% of the outstanding shares as of June end. KENVUE In October 2024, Starboard Value took a significant stake in the Band-Aid maker, criticizing the weak performance of its skin health segment, which houses Neutrogena, Aveeno and other brands. After a proxy battle, the companies reached a deal in early 2025 that gave Starboard CEO Jeffrey Smith and two independent directors board seats. CVS HEALTH In November, CVS Health added Glenview Capital's top boss and three others to its board as part of a deal with the hedge fund. The company had been under pressure from investors, including Glenview, to improve operations after missing financial targets several times due to rising medical costs in its health insurance business. Glenview reduced its stake in the company after CVS posted strong results in May. Sign in to access your portfolio
Yahoo
4 minutes ago
- Yahoo
BrainsWay Acquires Minority-Stake in Axis Integrated Mental Health
The Investment is part of BrainsWay's ongoing strategy to acquire minority positions in leading U.S. mental health providers to help them raise awareness for and expand access to transformative care BURLINGTON, Mass. and JERUSALEM, Aug. 20, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ('BrainsWay' or the 'Company'), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it has entered into a strategic equity financing agreement with Axis Management Company, Inc. ('Axis Integrated Mental Health' or 'Axis'), a management services organization servicing several mental health clinics in Colorado. Under the terms of the agreement, BrainsWay will invest $2.3 million initially, and an additional potential $1 million milestone-based investment, for a minority position in Axis in the form of a preferred, annually compounding security. The agreement also provides for a redemption mechanism relating to the shares. 'Our minority-stake investment in Axis follows our previous investment in Stella, and is part of BrainsWay's broader initiative to accelerate access to and awareness of innovative mental health treatments, including Deep TMS Therapy, while continuing to maintain our core focus on advancing our scientific and technological capabilities to ensure best-in-class support for all our customers. Within this strategy, our investments provide capital injections into high performing healthcare providers, which then allows these businesses to invest in growth drivers and launch new locations,' said Hadar Levy, Chief Executive Officer of BrainsWay. 'We see tremendous opportunities for these healthcare providers to offer expanded services and grow their businesses once they secure the necessary capital.' 'Axis offers a robust clinical services platform and is committed to achieving rapid growth and excellent patient outcomes. We are thrilled to support and collaborate with them as their business continues to scale from a well-respected regional platform to one with a larger footprint, enhancing their delivery of life-changing care to additional patients,' concluded Mr. Levy. 'Our partnership with BrainsWay was born out of a mutual desire to deliver the best cutting-edge mental health treatments to the communities we serve,' stated Chris Perez, Chief Executive Officer of Axis. 'Given the peerless reputation of BrainsWay and its proprietary Deep TMS technology, we realize the value this strategic partnership will provide as we further advance in our mission of putting patients first through our best-in-class support.' About BrainsWay BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit About Axis Axis Integrated Mental Health services its leading mental health practices, which are dedicated to transforming lives through a truly comprehensive, integrative model of care. With a team of board-certified specialists combining modern psychiatry and psychotherapy with advanced treatments including Deep TMS™ and Spravato®, Axis utilizes an evidence-based, holistic therapeutic approach to treat patients, all through a single, coordinated care experience under one roof. For more information, please visit Forward-Looking Statement This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words 'intends,' 'may,' 'will,' 'plans,' 'expects,' 'anticipates,' 'projects,' 'predicts,' 'estimates,' 'aims,' 'believes,' 'hopes,' 'potential' or similar words, and also includes any financial guidance and projections contained herein. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the failure of our investments in management services organizations and/or other clinic-related entities to produce profitable returns; inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company's anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company's intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading 'Risk Factors' in the Company's filings with the U.S. Securities and Exchange Commission. Contacts: BrainsWay:Ido MaromChief Financial Investors:Brian RitchieLifeSci Advisors LLCbritchie@ in to access your portfolio
Yahoo
4 minutes ago
- Yahoo
Chewy Announces Fiscal Second Quarter 2025 Financial Results Conference Call
PLANTATION, Fla., August 20, 2025--(BUSINESS WIRE)--Chewy, Inc. (NYSE: CHWY) ("Chewy"), a trusted destination for pet parents and partners everywhere, announced today that it will report fiscal second quarter 2025 financial results before the market opens on Wednesday, September 10, 2025. Management will host a conference call and webcast to discuss the company's financial results at 8:00 am ET. To access the conference call by phone, please visit this link for registration (Phone Registration Link) to be provided with dial in details, including a unique PIN to access the conference call. To avoid delays, we encourage participants to register in advance or at a minimum 15 minutes before the start of the call. A live audio webcast can be accessed on the company's investor relations website at and a replay of the conference call will also be available on the company's investor relations website for at least 90 days following the event. Chewy Fiscal Second Quarter 2025 Financial Results Conference CallWhen: Wednesday, September 10, 2025Time: 8:00 am ETLive webcast and replay: Conference call registration: Phone Registration Link About Chewy Our mission is to be the most trusted and convenient destination for pet parents and partners everywhere. We believe that we are the preeminent online source for pet products, supplies and prescriptions as a result of our broad selection of high-quality products and services, which we offer at competitive prices and deliver with an exceptional level of care and a personal touch to build brand loyalty and drive repeat purchasing. We seek to continually develop innovative ways for our customers to engage with us, as our websites and mobile applications allow our pet parents to manage their pets' health, wellness, and merchandise needs, while enabling them to conveniently shop for our products. We partner with approximately 3,200 of the best and most trusted brands in the pet industry, and we create and offer our own private brands. Through our websites and mobile applications, we offer our customers approximately 130,000 products and services offerings, to bring what we believe is a high-bar, customer-centric experience to our customers. View source version on Contacts Investor Contact: Natalie Nowakir@ Media Contact: Diane Pelkeydpelkey@
